Complex Fluid Balance and Circulation II: Coagulation, Hemostasis, and Transfusion Medicine

Complete Blood Count Reference Values and Clinical Indications

  • Red Blood Cells (RBC): Men: 4.0−5.5×1012/L4.0 - 5.5 \times 10^{12}/\text{L}; Women: 3.5−5.0×1012/L3.5 - 5.0 \times 10^{12}/\text{L}

  • Hemoglobin (HGB): Men: 140−180 g/L140 - 180\,\text{g/L}; Women: 120−160 g/L120 - 160\,\text{g/L} (reflects oxygenation and perfusion; low indicates anemia)

  • Hematocrit (Hct): 0.38−0.50 L/L0.38 - 0.50\,\text{L/L} (percentage by volume of RBCs; decreased in fluid overload, elevated in dehydration)

  • White Blood Cells (WBC): 4.0−11.0×109/L4.0 - 11.0 \times 10^9/\text{L} (immunity indicator; high signals infection, low signals impaired immunity)

  • Platelets (Plt): 150−400×109/L150 - 400 \times 10^9/\text{L} (clotting component; counts below normal increase bleeding risk)

  • Prothrombin Time (PT): 11−13.5 seconds11 - 13.5\,\text{seconds} (evaluates extrinsic pathway; elevated time indicates impaired clotting)

Hemostasis Mechanisms and Coagulation Cascade

Primary Hemostasis: Exposure, Adhesion, Activation, and Aggregation

  • Primary Hemostasis:

    • Local vasoconstriction limits immediate blood flow to the damaged area.

    • Vascular endothelial damage exposes subendothelial collagen, triggering the release of Von Willebrand Factor (VWF).

    • Platelet Plug Formation:

    • Adhesion: Glycoprotein Ib (GPIb) on platelets binds to exposed VWF on collagen.

    • Activation: Platelets alter shape to increase stickiness.

    • Secretion: Degranulation releases adenosine diphosphate (ADP), thromboxane A2, serotonin, and calcium (Ca2+\text{Ca}^{2+}).

    • Aggregation: Fibrinogen cross-links platelets via glycoprotein IIb/IIIa (GPIIb/IIIa) receptors to form an initial, unstable plug.

Intrinsic, Extrinsic, and Common Coagulation Pathways

  • Secondary Hemostasis (Coagulation Cascade):

    • Intrinsic Pathway: Activated by surface contact; initiates with Factor XII →\rightarrow Factor XIIa, proceeding via Factor XI, Factor IX, and Factor VIII. Monitored by activated Partial Thromboplastin Time (aPTT, normal 25−30 seconds25 - 30\,\text{seconds}).

    • Extrinsic Pathway: Triggered by tissue damage exposing Tissue Factor, which complexes with Factor VII to form Factor VIIa. Monitored by Prothrombin Time (PT, normal 11−13.5 seconds11 - 13.5\,\text{seconds}) and International Normalized Ratio (INR, normal 0.8−1.10.8 - 1.1).

    • Common Pathway: Both pathways activate Factor X to Factor Xa. Factor Xa converts Prothrombin (Factor II) into Thrombin (Factor IIa). Thrombin cleaves Fibrinogen (Factor I) into Fibrin monomers, which are cross-linked by Factor XIIIa into a stable fibrin clot.

  • Tertiary Hemostasis: Remodeling of the fibrin clot restores normal tissue structure.

  • Vitamin K Cycle:

    • Required for gamma-glutamyl-carboxylase activation of clotting factors II, VII, IX, and X, as well as regulatory Proteins C, S, and Z.

    • Vitamin K epoxide reductase regenerates active reduced vitamin K; inhibition or dietary deficiency produces clinical coagulopathy.

Hypocoagulability and Bleeding Disorders

  • Clinical Manifestations of Bleeding:

    • Petechiae, ecchymoses, gingival bleeding, epistaxis, hematuria, hematemesis, melena/hematochezia, and menorrhagia.

    • Coagulation labs show prolonged PT/INR and aPTT.

  • Inherited Coagulopathies:

    • Inherited Thrombocytopenia: Caused by decreased platelet production or structural platelet abnormalities.

    • Hemophilia A: Congenital deficiency of Factor VIII.

    • Hemophilia B: Congenital deficiency of Factor IX.

    • von Willebrand's Disease: Type 1 features quantitative deficiency of VWF; Type 2 features qualitative structural defects in VWF.

    • FactorFirst Management Protocol:

    • Prioritize prompt infusion of factor concentrates before diagnostic investigations ("Factor First").

    • Avoid invasive procedures (e.g., arterial punctures) without factor cover.

    • Contraindicated: Intramuscular (IM) injections and acetylsalicylic acid (ASA).

    • Emergency categories: Life- or limb-threatening bleeds (intracranial, neck, chest, abdomen, pelvis, spine, iliopsoas, compartment syndrome) require immediate intervention.

  • Acquired Coagulopathies:

    • Leukemias: Malignant leukocyte proliferation causing bone marrow failure, anemia, leukopenia, and thrombocytopenia.

    • HELLP Syndrome: Obstetrical crisis defined by Hemolysis, Elevated Liver enzymes, and Low Platelets.

    • Liver Dysfunction: Impairs synthesis of coagulation factors, prolonging PT/INR and aPTT.

    • Disseminated Intravascular Coagulation (DIC):

    • Triggered by trauma, sepsis, malignancy, shock, or obstetrical emergencies.

    • Pathophysiology: Uncontrolled thrombin generation leads to systemic microvascular thrombosis, followed by consumption of clotting factors and platelets, resulting in catastrophic hemorrhage.

Hypercoagulability and Antithrombotic Pharmacology

  • Hypercoagulable States:

    • Etiologies: Polycythemia, thrombocytosis, genetic thrombophilias (Protein C deficiency, Prothrombin gene mutation, Factor V Leiden), antiphospholipid syndrome, and sepsis.

    • Complications: Deep vein thrombosis (DVT), pulmonary embolism (PE), ischemic stroke, and myocardial infarction (MI).

    • Paradoxical Hypocoagulation: Occurs when elevated platelet counts consist of dysmorphic, non-functional platelets, manifesting as bleeding.

  • Antiplatelet and Anticoagulant Agents:

    • Acetylsalicylic Acid (ASA): NSAID that irreversibly inhibits platelet aggregation. Risk of gastric ulceration and bleeding.

    • Heparin (Unfractionated Heparin - UFH):

    • Potentiates antithrombin, inactivates thrombin, and blocks Factor Xa.

    • Delivered via weight-based IV nomograms; monitored closely with aPTT.

    • Complication: Heparin-Induced Thrombocytopenia (HIT). Antidote: Protamine sulfate.

    • Low-Molecular Weight Heparin (LMWH):

    • Agents: Dalteparin, Enoxaparin, Fondaparinux. Administered subcutaneously; routine coagulation monitoring is not required.

    • Warfarin (Coumadin):

    • Vitamin K antagonist suppressing synthesis of Factors II, VII, IX, and X. Monitored via PT/INR. Antidote: Vitamin K.

    • Direct Oral Anticoagulants (DOACs):

    • Agents: Apixaban, Dabigatran, Rivaroxaban. Direct Factor Xa or thrombin inhibitors; do not require routine coagulation monitoring.

Blood Transfusion Protocols and Component Therapy

  • Using Blood Wisely Quality Standards:

    • At least 65%65\% of red blood cell transfusion episodes must be single-unit orders.

    • At least 80%80\% of inpatient red blood cell transfusions must occur at a pre-transfusion Hemoglobin ≤80 g/L\le 80\,\text{g/L}.

ABO and Rh Blood Type Donor-Recipient Compatibility

  • Compatibility Matrix:

    • Type O−O^- is the universal RBC donor; Type AB+AB^+ is the universal RBC recipient.

    • Type & Screen establishes ABO/Rh status; crossmatch tests recipient serum against donor red blood cells.

  • Pre-Transfusion Safety & Preparation:

    • Informed consent obtained by the physician (exempt only in immediate life threats lacking patient capacity, substitute decision-maker, or prior refusal).

    • Complete practitioner order containing patient identifiers, product type, volume/units, and infusion rate.

    • Baseline physical assessment and vital signs documented within 30 minutes30\,\text{minutes} prior to initiation.

Intravenous Blood Administration Tubing Configuration

  • Administration Standards:

    • Blood must be initiated within 30 minutes30\,\text{minutes} of leaving the blood bank and completely infused within 4 hours4\,\text{hours}.

    • Requires dedicated filtered Y-tubing primed with normal saline (0.9% NaCl0.9\%\,\text{NaCl}).

    • Mandatory independent double check verifying the 5 Rights: Right Patient, Right Product, Right Amount, Right Rate, Right Time.

    • Infusion initiated slowly at ∼50 mL/hr\sim 50\,\text{mL/hr} for the first 15 minutes15\,\text{minutes}; repeat vital signs at 15 minutes15\,\text{minutes}, then hourly until completion.

  • Blood Components:

    • Packed Red Blood Cells (PRBCs): Indicated for anemia or blood loss with compromised perfusion. One unit typically increases Hemoglobin by ∼10 g/L\sim 10\,\text{g/L} and Hematocrit by ∼3%\sim 3\% (measured 4−6 hours4 - 6\,\text{hours} post-infusion).

    • Fresh Frozen Plasma (FFP): Indicated for multiple coagulation factor deficiencies, liver disease, or massive transfusion volume expansion.

    • Platelets: Indicated for severe thrombocytopenia (<150×109/L< 150 \times 10^9/\text{L}), congenital dysfunction, or antiplatelet medication toxicity; typically infused over 60 minutes60\,\text{minutes}.

Transfusion Reactions and Emergency Response

  • Acute Transfusion Reaction Classifications:

    • Minor Allergic Reaction (1 in 1001\,\text{in}\,100): Urticaria, pruritus, localized erythema. Interventions: slow transfusion, administer antihistamines.

    • Anaphylaxis (1 in 40,0001\,\text{in}\,40,000): Severe dyspnea, wheezing, angioedema, airway compromise. Intervention: immediately stop transfusion, initiate emergency resuscitation.

    • Febrile Non-Hemolytic Reaction (1 in 3001\,\text{in}\,300): Donor leukocyte/cytokine mediated; causes fever rise and rigors. Interventions: slow transfusion, administer antipyretics.

    • Bacterial Sepsis (1 in 10,0001\,\text{in}\,10,000 symptomatic in platelets; 1 in 250,0001\,\text{in}\,250,000 in RBCs): Rigors, high fever, profound hypotension, circulatory collapse. Intervention: immediately stop transfusion, obtain blood cultures, initiate IV antibiotics.

    • Acute Hemolytic Transfusion Reaction (AHTR) (1 in 40,0001\,\text{in}\,40,000): ABO incompatibility causing intravascular hemolysis; presents with fever, flank/back pain, hypotension, and dark/red urine (hemoglobinuria). Intervention: immediately stop transfusion.

    • Transfusion-Related Acute Lung Injury (TRALI) (1 in 12,0001\,\text{in}\,12,000): Non-cardiogenic pulmonary edema with acute hypoxemia (SpO2<90%\text{SpO}_2 < 90\% on room air) and bilateral pulmonary infiltrates. Intervention: immediately stop transfusion, provide ventilatory support.

    • Transfusion-Associated Circulatory Overload (TACO) (1 in 1001\,\text{in}\,100): Volume overload occurring in cardiac or renal compromise; presents with hypertension, tachypnea, tachycardia, pulmonary crackles, and orthopnea. Interventions: slow or stop transfusion, administer loop diuretics, position upright.

    • Hypotensive Reaction (Very rare): Bradykinin-mediated vasodilation, typically seen in patients concurrently taking ACE inhibitors. Intervention: immediately stop transfusion.

  • Emergency Reaction Protocol:

    1. Stop transfusion immediately.

    2. Maintain patent IV access with normal saline using new IV tubing (do not flush blood remaining in existing line).

    3. Conduct immediate physical assessment and vital sign check.

    4. Re-verify all identification tags, labels, and blood unit numbers.

    5. Notify primary health care provider and blood bank facility immediately.

    6. Send blood component bag, administration tubing, and required lab specimens to the blood bank for evaluation.